title: Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?
abstract: The impact of ER levels on the response to tamoxifen was evaluated in 1,623 postmenopausal primary breast cancer patients treated at our center (median follow-up 8.2 years). In patients receiving adjuvant tamoxifen a significantly longer disease-free survival (DFS) was observed when ER levels were elevated (p<0.00001). Very high ER (>424 fmol/mg protein) appeared to be detrimental in node-negative patients not treated with tamoxifen.
authors.affiliation: Department of Radiotherapy, Centre René Huguenin, St-Cloud, France.
authors.forename: J L
authors.initials: JL
authors.lastname: Floiras
authors.forename: K
authors.initials: K
authors.lastname: Hacene
authors.forename: F
authors.initials: F
authors.lastname: Turpin
authors.forename: F
authors.initials: F
authors.lastname: Spyratos
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004967:Estrogens; D005260:Female; D006801:Humans; D015993:Life Tables; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology; D015411:Mastectomy, Modified Radical; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017698:Postmenopause; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D012189:Retrospective Studies; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D004967:Estrogens; D009363:Neoplasm Proteins; D011960:Receptors, Estrogen; D013629:Tamoxifen